Neuropathic Pain Market

Market Overview:

The 7 major neuropathic pain markets reached a value of US$ 5.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.7% during 2024-2034.

The neuropathic pain market has been comprehensively analyzed in IMARC's new report titled "Neuropathic Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neuropathic pain is a type of chronic pain that is caused by damage or dysfunction of the nerves. Some of the common symptoms include burning, shooting, or tingling sensations, numbness, heightened sensitivity to touch, etc. The pain can be constant or intermittent and may be felt in a specific area or spread throughout the body. Additionally, individuals with neuropathic pain may experience weakness or loss of sensation in the affected areas. The diagnosis typically involves a combination of medical history, physical examination, and tests to determine the presence of neuropathic pain. During a physical exam, the healthcare provider may look for signs of nerve damage, such as weakness, loss of sensation, or reflex changes, and may perform some tests to assess the function of the affected nerves. Several diagnostic tests, including nerve conduction studies or imaging tests, are done to confirm the presence of nerve damage and identify the specific cause of the pain.

The increasing prevalence of chronic diseases that cause nerve damage and the rising incidences of peripheral nerve injuries are primarily driving the global neuropathic pain market. In addition to this, the inflating usage of anticonvulsants and tricyclic antidepressants for stabilizing nerve cells and reducing the release of certain neurotransmitters is further propelling the market growth. Moreover, the widespread adoption of nerve blocks, such as epidural injections, for blocking the transmission of pain signals to the brain is also creating a positive outlook for the market. Apart from this, the emerging popularity of transcutaneous electrical nerve stimulation (TENS), a non-invasive pain management therapy that uses low-voltage electrical currents to stimulate nerve fibers and relieve pain, is also bolstering the market growth. Furthermore, the increasing utilization of psychological treatments, including cognitive-behavioral therapy and mindfulness-based interventions, for managing the emotional and psychological aspects of neuropathic pain is acting as another significant growth-inducing factor. Additionally, the rising adoption of nerve stimulation techniques, such as spinal cord stimulation, peripheral nerve stimulation, deep brain stimulation, etc., to alleviate symptoms by stimulating specific nerves or areas of the brain associated with the pain is expected to drive the global neuropathic pain market in the coming years.

IMARC Group’s new report provides an exhaustive analysis of the neuropathic pain market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neuropathic pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neuropathic pain market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the neuropathic pain market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the neuropathic pain market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current neuropathic pain marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the neuropathic pain market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the neuropathic pain market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the neuropathic pain market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of neuropathic pain across the seven major markets?
• What is the number of prevalent cases (2018-2034) of neuropathic pain by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of neuropathic pain by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of neuropathic pain by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with neuropathic pain across the seven major markets?
• What is the size of the neuropathic pain patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of neuropathic pain?
• What will be the growth rate of patients across the seven major markets?
   

Neuropathic Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for neuropathic pain drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neuropathic pain market?
• What are the key regulatory events related to the neuropathic pain market?
• What is the structure of clinical trial landscape by status related to the neuropathic pain market?
• What is the structure of clinical trial landscape by phase related to the neuropathic pain market?
• What is the structure of clinical trial landscape by route of administration related to the neuropathic pain market?